Barinthus Bio slashes headcount by 25% and refocuses pipeline
2024-06-13
临床2期免疫疗法临床结果临床1期
Preview
来源: Pharmaceutical Technology
Barinthus Bio is a UK-based T cell therapy specialist. Image credit: Shutterstock / ymart.
Much like the mythological navigator from which it takes its name, Barinthus Biotherapeutics is steering a new course of pipeline prioritisation and restructuring by shelving its prostate cancer candidate and a major workforce reduction.
Recommended Buyer's Guides
Preview
来源: Pharmaceutical Technology
Buyer's Guide
Leading Guide to Packaging Materials, Containers and Containment Services for the Pharmaceutical Industry
Preview
来源: Pharmaceutical Technology
Buyer's Guide
Top Guide for Drug Delivery Systems
The UK-based T cell specialist – formerly known as Vaccitech – said it will prioritise its pipeline to focus on two of its immunotherapy candidates, VTP-300 and VTP-1000, in chronic hepatitis B and coeliac disease indications respectively.
As part of the pipeline shuffle, the biopharma said that it expects to undergo a restructuring which will include reducing its employee number by around a quarter. The company currently has a headcount of around 130 employees, according to GlobalData.
GlobalData is the parent company of Pharmaceutical Technology.
See Also:Takeda signs option agreement with Ascentage for CML drug
Preview
来源: Pharmaceutical Technology
UK’s new Netflix-style funding model for antibiotics goes live
Preview
来源: Pharmaceutical Technology
Barinthus also plans to extend its cash runway into Q2 of 2026, further down the road it previously projected its coffers to reach which was until Q4 2025.
The decision for VTP-300’s focus comes on the back of recent positive interim data from a pair of Phase II trials. The results, unveiled at the European Association for the Study of the Liver (EASL), demonstrated the drug’s potential to “significantly reduce and maintain hepatitis B surface antigen (HBsAg) levels and achieve undetectable HBsAg levels in patients with chronic hepatitis B.”
Barinthus’ CEO Bill Enright said: “We believe that VTP-300 has great potential to do so as part of a functional cure regimen for Hepatitis B. With this pipeline prioritisation, we put the company in a strong position to maximise the probability of success.”
VTP-1000’s prioritisation meanwhile was based on “encouraging” preclinical data. Barinthus’ candidate is designed to induce gluten-specific T regulatory cells and reduce gluten-specific T effector cell responses, thereby dampening the immune response seen in coeliac patients. A Phase I trial is expected to commence in Q3 2024.
As VTP-300 and VTP-1000 advance, the company’s prostate cancer candidate VTP-850 appears to be getting sidelined. While a Phase I trial with the immunotherapeutic candidate will be completed, Barinthus did not reveal any further plans. VTP-850 appears on the company’s website alongside infectious disease candidate VTP-200, which has just been evaluated in a Phase Ib/II trial. The trial reached its primary safety endpoint but fell short of efficacy, based on results announced in April this year.
Barinthus is not the only company to trim its workforce this year. Senti Bio cut 37% of its employees in January in an attempt to extend its cash runway, followed by Xilio firing 21% of its workforce in a pipeline reprioritisation effort. Most recently, Erasca reduced its headcount by around 18% after shutting down three clinical programmes.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。